Clinical Trial Update: A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer

View source ↗

Summary

Non-interventional study evaluating Aromasin (exemestane) as adjuvant treatment for invasive early breast cancer; results have been posted following termination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Invasive Early Breast Cancer | Status: TERMINATED | Results posted: 2014-01-22